Status:

RECRUITING

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Lead Sponsor:

Fujian Cancer Hospital

Collaborating Sponsors:

Fujian Medical University Affiliated Nanping First Hospital

The First Hospital Affiliated to Fujian Medical University

Conditions:

Cervical Cancer

Eligibility:

FEMALE

18-80 years

Brief Summary

Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal juncti...

Detailed Description

1. To explore the efficacy of Cadonilimab in the treatment of persistent, recurrent or metastatic cervical cancer. The size of each diameter of the tumor before and after treatment was measured on...

Eligibility Criteria

Inclusion

  • •Persistent, recurrent or metastatic cervical cancer;
  • The pathological types are squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma;
  • No combination with other multiple primary cancers;
  • MRI before treatment Or CT examination, according to RECIST evaluation standards, there is at least one measurable lesion;
  • ECOG score 0-1 points.
  • Subjects gave informed consent, voluntarily cooperated with clinical follow-up, and signed informed consent forms.

Exclusion

  • Patients with other histopathological types of cervical cancer, such as small cell carcinoma, clear cell carcinoma, sarcoma, etc.;
  • Previous treatment with immune checkpoint inhibitors;
  • There are drug contraindications, such as liver function Insufficiency, renal insufficiency, etc.
  • The patient withdraws the informed consent;
  • The researcher determines that the patient is not suitable to participate in this clinical study.

Key Trial Info

Start Date :

September 7 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06140589

Start Date

September 7 2024

End Date

December 1 2026

Last Update

September 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

No. 420 Fuma Road, Jin'an District, Fuzhou City, Fujian Province

Fuzhou, Fujian, China, 350074